Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Withdrawn study sought to stop brain 'Storms' after blood clot surgery

NCT ID NCT04966546

First seen Feb 19, 2026

Summary

This study planned to test whether the drug memantine could reduce harmful brain waves called spreading depolarizations after surgery for chronic subdural hematoma, a common condition in older adults where fluid compresses the brain. The trial was withdrawn before any participants were enrolled, so no data was collected. The goal was to see if blocking these brain waves could prevent post-surgery confusion or weakness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SUBDURAL HEMATOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of New Mexico

    Albuquerque, New Mexico, 87131, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Memantine Hydrochloride

What this could lead to

If it had worked, this could point toward a treatment to reduce confusion or weakness after brain surgery for chronic subdural hematoma.

What could go wrong

The trial was withdrawn before enrolling anyone, so no results exist. It was a very early feasibility study, and memantine's effect on these brain waves was unproven.

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.